Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study. 2022

Nefertiti C duPont, and Danielle Enserro, and Mark F Brady, and Katherine Moxley, and Joan L Walker, and Casey Cosgrove, and Kristin Bixel, and Krishnansu S Tewari, and Premal Thaker, and Andrea E Wahner Hendrickson, and Stephen Rubin, and Keiichi Fujiwara, and A Catherine Casey, and John Soper, and Robert A Burger, and Bradley J Monk
North Houston Gynecologic Oncology Surgeons, Shenandoah, TX, USA. Electronic address: ndupont@gynonchouston.com.

Age and ethnicity are among several factors that influence overall survival (OS) in ovarian cancer. The study objective was to determine whether ethnicity and age were of prognostic significance in women enrolled in a clinical trial evaluating the addition of bevacizumab to front-line therapy. Women with advanced stage ovarian, primary peritoneal, or fallopian tube cancer were enrolled in a phase III clinical trial. All women had surgical staging and received adjuvant chemotherapy with one of three regimens. Cox proportional hazards models were used to evaluate the relationship between OS with age and race/ethnicity among the study participants. One-thousand-eight-hundred-seventy-three women were enrolled in the study. There were 280 minority women and 328 women over the age of 70. Women age 70 and older had a 34% increase risk for death when compared to women under 60 (HR = 1.34; 95% CI 1.16-1.54). Non-Hispanic Black women had a 54% decreased risk of death with the addition of maintenance bevacizumab (HR = 0.46, 95% CI:0.26-0.83). Women of Asian descent had more hematologic grade 3 or greater adverse events and a 27% decrease risk of death when compared to non-Hispanic Whites (HR = 0.73; 95% CI: 0.59-0.90). Non-Hispanic Black women showed a decreased risk of death with the addition of bevacizumab and patients of Asian ancestry had a lower death rate than all other minority groups, but despite these clinically meaningful improvements there was no statistically significant difference in OS among the groups.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D010534 Peritoneal Neoplasms Tumors or cancer of the PERITONEUM. Peritoneal Carcinomatosis,Peritoneal Surface Malignancy,Carcinomatosis, Peritoneal,Malignancy, Peritoneal Surface,Neoplasm, Peritoneal,Peritoneal Carcinomatoses,Peritoneal Neoplasm,Peritoneal Surface Malignancies,Surface Malignancy, Peritoneal
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D001741 Black or African American A person having origins in any of the black racial groups of Africa (https://www.federalregister.gov/documents/1997/10/30/97-28653/revisions-to-the-standards-for-the classification-of-federal-data-on-race-and-ethnicity). In the United States it is used for classification of federal government data on race and ethnicity. Race and ethnicity terms are self-identified social construct and may include terms outdated and offensive in MeSH to assist users who are interested in retrieving comprehensive search results for studies such as in longitudinal studies. African American,African Americans,African-American,Afro-American,Afro-Americans,Black Americans,Blacks,Negroes,African-Americans,Negro,Afro American,Afro Americans,American, African,American, Black,Black American
D005006 Ethnicity A group of people with a common cultural heritage that sets them apart from others in a variety of social relationships. Ethnic Groups,Nationality,Ethnic Group,Nationalities
D005185 Fallopian Tube Neoplasms Benign or malignant neoplasms of the FALLOPIAN TUBES. They are uncommon. If they develop, they may be located in the wall or within the lumen as a growth attached to the wall by a stalk. Cancer of the Fallopian Tube,Fallopian Tube Cancer,Cancer, Fallopian Tube,Cancers, Fallopian Tube,Fallopian Tube Cancers,Fallopian Tube Neoplasm,Neoplasm, Fallopian Tube,Neoplasms, Fallopian Tube
D005260 Female Females
D006630 Hispanic or Latino A person of Cuban, Mexican, Puerto Rican, South or Central American, or other Spanish culture or origin, regardless of race (https://www.federalregister.gov/documents/1997/10/30/97-28653/revisions-to-the-standards-for-the-classification-of-federal-data-on-race-and-ethnicity). In the United States it is used for classification of federal government data on race and ethnicity. Race and ethnicity terms are self-identified social construct and may include terms outdated and offensive in MeSH to assist users who are interested in retrieving comprehensive search results for studies such as in longitudinal studies. Cuban Americans,Hispanic Americans,Latin Americans, US,Latinas,Latinos,Latinx,Puerto Ricans,Spanish Americans,Hispanics,American, Hispanic,American, US Latin,Cuban American,Hispanic American,Hispanic or Latinos,Latin American, US,Latina,Latino,Puerto Rican,Spanish American,US Latin American,US Latin Americans

Related Publications

Nefertiti C duPont, and Danielle Enserro, and Mark F Brady, and Katherine Moxley, and Joan L Walker, and Casey Cosgrove, and Kristin Bixel, and Krishnansu S Tewari, and Premal Thaker, and Andrea E Wahner Hendrickson, and Stephen Rubin, and Keiichi Fujiwara, and A Catherine Casey, and John Soper, and Robert A Burger, and Bradley J Monk
October 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Nefertiti C duPont, and Danielle Enserro, and Mark F Brady, and Katherine Moxley, and Joan L Walker, and Casey Cosgrove, and Kristin Bixel, and Krishnansu S Tewari, and Premal Thaker, and Andrea E Wahner Hendrickson, and Stephen Rubin, and Keiichi Fujiwara, and A Catherine Casey, and John Soper, and Robert A Burger, and Bradley J Monk
August 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Nefertiti C duPont, and Danielle Enserro, and Mark F Brady, and Katherine Moxley, and Joan L Walker, and Casey Cosgrove, and Kristin Bixel, and Krishnansu S Tewari, and Premal Thaker, and Andrea E Wahner Hendrickson, and Stephen Rubin, and Keiichi Fujiwara, and A Catherine Casey, and John Soper, and Robert A Burger, and Bradley J Monk
February 2018, Gynecologic oncology,
Nefertiti C duPont, and Danielle Enserro, and Mark F Brady, and Katherine Moxley, and Joan L Walker, and Casey Cosgrove, and Kristin Bixel, and Krishnansu S Tewari, and Premal Thaker, and Andrea E Wahner Hendrickson, and Stephen Rubin, and Keiichi Fujiwara, and A Catherine Casey, and John Soper, and Robert A Burger, and Bradley J Monk
May 2017, Cancer,
Nefertiti C duPont, and Danielle Enserro, and Mark F Brady, and Katherine Moxley, and Joan L Walker, and Casey Cosgrove, and Kristin Bixel, and Krishnansu S Tewari, and Premal Thaker, and Andrea E Wahner Hendrickson, and Stephen Rubin, and Keiichi Fujiwara, and A Catherine Casey, and John Soper, and Robert A Burger, and Bradley J Monk
May 2008, Cancer,
Nefertiti C duPont, and Danielle Enserro, and Mark F Brady, and Katherine Moxley, and Joan L Walker, and Casey Cosgrove, and Kristin Bixel, and Krishnansu S Tewari, and Premal Thaker, and Andrea E Wahner Hendrickson, and Stephen Rubin, and Keiichi Fujiwara, and A Catherine Casey, and John Soper, and Robert A Burger, and Bradley J Monk
September 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Nefertiti C duPont, and Danielle Enserro, and Mark F Brady, and Katherine Moxley, and Joan L Walker, and Casey Cosgrove, and Kristin Bixel, and Krishnansu S Tewari, and Premal Thaker, and Andrea E Wahner Hendrickson, and Stephen Rubin, and Keiichi Fujiwara, and A Catherine Casey, and John Soper, and Robert A Burger, and Bradley J Monk
December 2016, Gynecologic oncology,
Nefertiti C duPont, and Danielle Enserro, and Mark F Brady, and Katherine Moxley, and Joan L Walker, and Casey Cosgrove, and Kristin Bixel, and Krishnansu S Tewari, and Premal Thaker, and Andrea E Wahner Hendrickson, and Stephen Rubin, and Keiichi Fujiwara, and A Catherine Casey, and John Soper, and Robert A Burger, and Bradley J Monk
December 2016, Gynecologic oncology,
Nefertiti C duPont, and Danielle Enserro, and Mark F Brady, and Katherine Moxley, and Joan L Walker, and Casey Cosgrove, and Kristin Bixel, and Krishnansu S Tewari, and Premal Thaker, and Andrea E Wahner Hendrickson, and Stephen Rubin, and Keiichi Fujiwara, and A Catherine Casey, and John Soper, and Robert A Burger, and Bradley J Monk
March 2018, International journal of cancer,
Nefertiti C duPont, and Danielle Enserro, and Mark F Brady, and Katherine Moxley, and Joan L Walker, and Casey Cosgrove, and Kristin Bixel, and Krishnansu S Tewari, and Premal Thaker, and Andrea E Wahner Hendrickson, and Stephen Rubin, and Keiichi Fujiwara, and A Catherine Casey, and John Soper, and Robert A Burger, and Bradley J Monk
October 2018, Gynecologic oncology,
Copied contents to your clipboard!